Vorinostat (NSC# 701852) in Patients with relapsed non-small cell lung cancer; A wisconsin oncology network phase II study

Journal of Thoracic Oncology

Volumn 4, Issue 4, 2009, Pages 522-526

  Traynor, Anne M ^a   Dubey, Sarita ^b   Eickhoff, Jens C ^a   Kolesar, Jill M ^a   Schell, Kathleen ^a   Huie, Michael S ^a   Groteluschen, David L ^c   Marcotte, Sarah M ^a   Hallahan, Courtney M ^a   Weeks, Hilary R ^a   Wilding, George ^a   Espinoza Delgado, Igor ^d   Schiller, Joan H ^e  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Green Bay Oncology   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Histone deacetylase inhibitors; Non small cell lung cancer; Phase II; Relapsed disease

Indexed keywords

VORINOSTAT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; DRUG ANTAGONISM; LUNG TUMOR; MIDDLE AGED; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 67649399669     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181952478     Document Type: Article

References (40)

1. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
3. Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006;24:5253-5258. (Pubitemid 46631370)
4. Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5025-5033. (Pubitemid 46631406)
5. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5:981-989. (Pubitemid 350080267)
6. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:3697-3702.
7. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004;101:540-545.
8. Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003;63:4460-4471.
9. Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A 2006;103: 15540-15545. (Pubitemid 44625628)
10. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:673-678. (Pubitemid 40282724)
11. Gridelli C, Rossi A, Maione P. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 2008;68:29-36. (Pubitemid 351864251)
12. Miyanaga A, Gemma A, Noro R, et al. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 2008;7:1923-1930.
13. Hershberger P, Owonikoko TK, Ramalingam S, Belani CP. The effect of p53 gene status on the interaction of vorinostat (suberoylanilide hydroxamic acid, SAHA) with carboplatin in non small cell lung cancer (NSCLC) cell lines. J Clin Oncol 2007;25(Suppl):581s.
14. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005;62:223-229. (Pubitemid 40591946)
15. Seo SK, Jin HO, Lee HC, et al. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol Pharmacol 2008;73:1005-1012.
16. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-7300. (Pubitemid 37413470)
17. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931. (Pubitemid 46218695)
18. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24:166-173. (Pubitemid 46630509)
19. Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007;13:3605-3610. (Pubitemid 46955122)
20. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-39. (Pubitemid 46053039)
21. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-3115. (Pubitemid 47218059)
22. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006;7:257-261. (Pubitemid 43280028)
23. Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008;109:182-186. (Pubitemid 351668320)
24. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (ZolinzaTM, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008;26:81-87.
25. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-b-cell lymphoma. Ann Oncol 2008;19:964-969. (Pubitemid 351627315)
26. Gatzemeier U, Blumenschein G, Fosella R, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006;24(Suppl):364s.
27. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 2007;356:125-134. (Pubitemid 46089673)
28. Goffin JR, Tu D. Phase II stopping rules that employ response rates and early progression. J Clin Oncol 2008;26:3715-3720.
29. Patel JD. Lung cancer in women. J Clin Oncol 2005;23:3212-3218. (Pubitemid 46211345)
30. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-1356.
31. Frew AJ, Lindemann RK, Martin BP, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 2008;105:11317-11322.
32. Zhang Y, Li N, Caron C, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003;22:1168-1179. (Pubitemid 36313600)
33. Bauer KA. Hypercoagulable states. In Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds.), Hematology: Basic Principles and Practice. Philadelphia, PA: Churchill Livingston, 2000. Pp. 2009-2039.
34. Cestari DM, Weine DM, Panageas KS, Segal AZ, DeAngelis LM. Stroke in patients with cancer: incidence and etiology. Neurology 2004; 62:2025-2030.
35. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007;321:892-901. (Pubitemid 46762687)
36. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004;89:1358-1367. (Pubitemid 38802657)
37. Faraco G, Pancani T, Formentini L, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006;70:1876-1884. (Pubitemid 44771903)
38. Schelman WR, Kolesar J, Schell K, et al. A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol 2007;25(Suppl):156s.
39. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003;102:3765-3774. (Pubitemid 37409399)
40. Denlinger CE, Rundall BK, Jones DR. Proteasome inhibition sensitizes non-small cell lung cancer to histone deactylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 2004;128:740-748.